文献速递心脑血管急症

稳定性心绞痛的诊断与管理:综述

Diagnosis and Management of Stable Angina: A Review.
PubMed 文献 · JAMA · 2021-01-01
一句话结论稳定性心绞痛首选冠状动脉CT血管成像诊断;血运重建仅用于心绞痛影响生活质量且优化药物治疗后仍有症状者,不降低死亡或心肌梗死。

该综述指出美国约1000万成人患稳定性心绞痛,年均心肌梗死或死亡风险3%至4%。冠状动脉CT血管成像因敏感性更高、特异性相当,成为稳定性心绞痛的一线诊断检查,并能检出其他无创影像无法识别的非阻塞性动脉粥样硬化。在他汀和抗血小板等常规治疗基础上,前蛋白转化酶枯草溶菌素/kexin 9型抑制剂、依折麦布、二十碳五烯酸乙酯及钠-葡萄糖共转运蛋白2抑制剂、胰高血糖素样肽1受体激动剂等新型药物改善心血管结局。随机临床试验显示,即使在中重度缺血,血运重建(主要为经皮冠状动脉介入治疗)相比单纯最佳药物治疗未改善死亡率或心肌梗死率,但能改善心绞痛和生活质量。

要点

  • 冠状动脉CT血管成像为稳定性心绞痛一线诊断检查,敏感性高于负荷影像检查、特异性相当。
  • 稳定性心绞痛年均心肌梗死或死亡风险为3%至4%。
  • 随机临床试验显示,血运重建(主要为经皮冠状动脉介入治疗)相比单纯最佳药物治疗未改善死亡率或心肌梗死率,即使在中重度缺血时亦然。
  • 血运重建相比抗心绞痛药物治疗能显著改善心绞痛和生活质量。
  • 应将心绞痛对生活质量的影响纳入临床评估,以协助决定是否行血运重建。

适用人群与场景

  • 美国成人稳定性心绞痛患者,心肌氧供不能满足需求导致心肌缺血。

处置流程与药物剂量

  • 强调优化生活方式和预防性药物(如降脂药和抗血小板药),以降低心血管事件和死亡风险。
  • 启动抗心绞痛药物(如β受体阻滞剂、硝酸酯类或钙通道阻滞剂)以改善心绞痛症状。
  • 经皮冠状动脉介入治疗应保留给心绞痛症状对生活质量产生负面影响的患者,通常在试用抗心绞痛药物治疗之后。
  • 与知情患者共同决策对有效治疗稳定性心绞痛很重要。

研究设计与关键结果

  • 综述指出,美国约1000万成人患稳定性心绞痛。
  • 冠状动脉CT血管成像因敏感性更高、特异性相当,成为稳定性心绞痛的一线诊断检查。
  • 冠状动脉CT血管成像可检出其他无创影像无法识别的非阻塞性动脉粥样硬化,改善风险评估并可能促使更恰当地分配预防性治疗。
  • 在常规治疗基础上加用前蛋白转化酶枯草溶菌素/kexin 9型抑制剂、依折麦布、二十碳五烯酸乙酯(针对血脂)和钠-葡萄糖共转运蛋白2抑制剂、胰高血糖素样肽1受体激动剂(针对2型糖尿病),改善稳定性缺血性心脏病患者的心血管结局。
  • 随机临床试验显示,血运重建(主要为经皮冠状动脉介入治疗)相比单纯最佳药物治疗未改善死亡率或心肌梗死率,即使在中重度缺血时亦然。
  • 血运重建相比抗心绞痛药物治疗在心绞痛和生活质量方面提供有意义的获益。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对稳定性心绞痛患者应强调优化生活方式和预防性药物(如降脂药和抗血小板药)以降低心血管事件和死亡风险。
  • 作者认为,应启动抗心绞痛药物(如β受体阻滞剂、硝酸酯类或钙通道阻滞剂)以改善心绞痛症状。
  • 作者认为,经皮冠状动脉介入治疗应保留给心绞痛症状对生活质量产生负面影响的患者,通常在试用抗心绞痛药物治疗之后。
  • 作者认为,与知情患者共同决策对有效治疗稳定性心绞痛很重要。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Nearly 10 million US adults experience stable angina, which occurs when myocardial oxygen supply does not meet demand, resulting in myocardial ischemia. Stable angina is associated with an average annual risk of 3% to 4% for myocardial infarction or death. Diagnostic tests and medical therapies for stable angina have evolved over the last decade with a better understanding of the optimal use of coronary revascularization.

OBSERVATIONS: Coronary computed tomographic angiography is a first-line diagnostic test in the evaluation of patients with stable angina due to higher sensitivity and comparable specificity compared with imaging-based stress testing. Moreover, coronary computed tomographic angiography allows detection of nonobstructive atherosclerosis that would not be identified with other noninvasive imaging modalities, improving risk assessment and potentially triggering more appropriate allocation of preventive therapies. Novel therapies treating lipids (proprotein convertase subtilisin/kexin type 9 inhibitors, ezetimibe, and icosapent ethyl) and type 2 diabetes (sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists) have improved cardiovascular outcomes in patients with stable ischemic heart disease when added to usual care. Randomized clinical trials showed no improvement in the rates of mortality or myocardial infarction with revascularization (largely by percutaneous coronary intervention) compared with optimal medical therapy alone, even in the setting of moderate to severe ischemia. In contrast, revascularization provides a meaningful benefit on angina and quality of life compared with antianginal therapies. Measures of the effect of angina on a patient's quality of life should be integrated into the clinic encounter to assist with the decision to proceed with revascularization.

CONCLUSIONS AND RELEVANCE: For patients with stable angina, emphasis should be placed on optimizing lifestyle factors and preventive medications such as lipid-lowering and antiplatelet agents to reduce the risk for cardiovascular events and death. Antianginal medications, such as β-blockers, nitrates, or calcium channel blockers, should be initiated to improve angina symptoms. Revascularization with percutaneous coronary intervention should be reserved for patients in whom angina symptoms negatively influence quality of life, generally after a trial of antianginal medical therapy. Shared decision-making with an informed patient is important for effective treatment of stable angina.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Joshi PH, de Lemos JA. Diagnosis and Management of Stable Angina: A Review. JAMA. 2021. PMID: 33944871. doi:10.1001/jama.2021.1527

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。